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It is known that patients with Hodgkin's disease have persis-
tent defects in both cellular and humoral immunity (Fisher et
al., 1980; Fuks et al., 1976; Weitzman et al., 1978). We have
been fortunate in being able to follow, for at least 10 years, a
group of consecutively treated patients with immunological
assessment being performed at presentation, during and after
treatment, at 1 year and 5 years remission (Hancock et al.,
1976, 1977a, b, 1982). In the 5 year study we found that
cellular immunity was still depressed and progressive falls in
serum immunoglobulins were noted; low IgG and IgM values
were particularly a feature of the patients who had had a
splenectomy and chemotherapy. Neutrophil counts were
lower then presentation values but lymphocyte and monocyte
counts were higher, mainly in splenectomised patients.
Sixteen of these patients have been fully reassessed; it is
now at least 10 years since the end of their treatment; 15 are
in remission; the other patient was found to have a recur-
rence of her Hodgkin's disease just after reassessment.
Tests performed were as described by Hancock et al.
(1977, 1982). These included peripheral blood counts, nitro-
blue tetrazolium (NBT) scores, leucocyte migration inhibition
(LMI) assay, lymphocyte transformation (LT) test to PHA,
T cell rosettes, intradermal skin tests and immunoglobulin
levels. Tests were performed at presentation, immediately
following radiotherapy or before the 3rd or 4th course of
intensive chemotherapy and, after 1 year, 5 years and 10
years remission. We have deliberately not incorporated newer
immunological techniques in the latest assessments in order
that this study should be strictly comparative.
Of the 15 patients in remission at 10 years, 8 had had a
splenectomy (3 radiotherapy, 5 chemotherapy) and 7 had not
(6 radiotherapy, 1 chemotherapy). The one patient who had
a recurrence had been treated initially with radiotherapy and
had not had a splenectomy. The results obtained were statis-
tically assessed; changes within the group as a whole (and
also according to splenectomy status) were analysed using
paired Student's t and x2 tests (see Table I).
Neutrophil counts fell with treatment before recovering to
near presentation levels at 10 years. There were no significant
changes in NBT values at any stage. The lymphocyte and
monocyte counts rose consistently after treatment to be
significantly higher at 10 years than at presentation. T cell
rosettes increased significantly at 5 years but fell slightly at 10
years though still remaining above presentation levels. Lym-
phocyte transformation responses were still depressed at 10
years compared to presentation but leucocyte migration res-
ponses recovered from 5 year values to return to presentation
values. Skin test responses were better at 10 years than at
presentation.
All immunoglobulin classes tested rose over the 10 year
period to return to near presentation levels. This is partic-
ularly notable since all classes were well below initial values
when tested at 5 years remission.
If the patients were divided into two groups (splenectomy
and no splenectomy) the main differences were in lymphocyte
counts where a greater increase was seen in the splenec-
tomised patients (4.22 x 10' 1` at 10 years compared to
1.79 x 1091- at presentation, P<0.05) and in IgM levels
where, although values rose in both groups returning to
presentation levels in the non-splenectomised patients, they
were still much lower at 10 years in the splenectomy group
(0.67 g -') despite a significant increase from 5 to 1O years.
The one patient who was found to have a recurrence of her
Hodgkin's disease shortly after the 10 year assessment was
found to have normal immunoglobulin levels, all three classes
tested being higher than at 5 years. Neutrophil, lymphocyte
and monocyte counts were also higher than at 5 years and all
within normal limits. However, cellular immune responses
were considerably impaired; leucocyte migration, lymphocyte
transformation and skin test responses were subnormal. T
cell rosettes were barely detectable (<1%)
Various changes in the immunological status of patients
with Hodgkin's disease have been described by other authors
in the follow-up period after radio and/or chemotherapy.
Fuks et al. (1976) in a study of 26 patients in complete
remission 12-111 months after radiation therapy showed
T-cell lymphocytopenia and significant impairment of in vitro
lymphocyte transformation responses persisting for up to 10
years post therapy; most of these patients had had a
laparotomy with splenectomy. Bjorkholm et al. (1977a, b)
also demonstrated persistent defects 15-18 months after
radiotherapy, and in a group of nine cured patients 10-28
years after treatment. However, Kun and Johnson (1975)
were unable to show any evidence of residual haematological
or immunological depression in 71 patients treated success-
fully by radiotherapy for their Hodgkin's disease 5 years
previously.
One important difference between these studies and our
own is that in our study we have followed each individual
patient consecutively from presentation to 10 years con-
tinuous remission. In summary, in our study, neutrophil
counts returned to presentation levels and overall lymphocyte
counts were well above presentation levels, although this was
mainly a feature of the patients who had had a splenectomy.
The acknowledged discrepancy between the various tests of
'cellular' immunocompetence is again highlighted: (i)
leucocyte migration responses, depressed at 5 years improved
at 10 years, (ii) lymphocyte transformation responses at 10
years were depressed compared with presentation and no
better than at 5 years, (iii) skin test reactivity improved
quickly and remained stable with remission, (iv) quanti-
tatively an increase in the T cell population was noted,
particularly at 5 years.
There appears to be no consistent relationship between
such findings and risk of infection. We reported at 5 years
(Hancock et al., 1982) that viral infections were not uncom-
mon during early follow-up except in the non-splenectomy/
radiotherapy group. In this further study the group as a
whole has been remarkably free of infection. Our initial fears
about increased risk in splenectomised patients (Hancock et
al., 1976) have not been justified, this despite the fact that,
whereas immunoglobulin levels rose generally over the 10
year period, IgM remained relatively low in the splenectomy
group.
In fact, in a separate review of our 116 patients who had
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Table I Follow-up assessments of immune status in the 16 patients with Hodgkin's disease in remission
Post I year S year 10 year
Presentation treatment remission remission remission
Neutrophil count 4.91 ± 0.54 3.26 ± 0.20b 4.76 ± 0.48 3.25 ± 0.40d 4.29 ± 0.41
cells x IO' l- I (mean ± s.e.)
(normal 1.5-7.5)
NBT score % 7.14 ± 0.93 nd nd 5.22 ± 0.43 5.92 + 0.29
(mean ± s.e.)
(normal 1-10)
Monocyte count 0.22 ± 0.04 0.23 + 0.04 0.34 + 0.06 0.44 ± 0.07c 0.52 ± O09b
cells x lO I ' (mean ± s.e.)
(normal 0.2-0.8)
Lymphocyte count 1.65 ± 0.13 1.33 ± 0.20 1.95 ± 0.24 2.61 ± 0.50 3.00 i 0.67d
cells x lO' - I (mean ± s.e.)
(normal 1.0-4.0)
T cells % 28.63 3.88 nd nd 52.85± 3.43a 36.73 ± 3.03
(mean ± s.e.)
(normal 40-80)
LT % normal 88 nd nd 54 53
LMI % normal 53 69 57 17a 64
Skin tests % positive 60 57 82 nd 85
Immunoglobulins g 1 ' (mean s.e.)
IgG (normal 7.5-- 14.0) 12.32 + 0.66 10.43 ± 0.87 10.84 ± 0.72 9.74± 0.75c 11.36 + 0.94
IgA (normal 1.0-3.0) 2.32 0.27 2.11 + 0.26 1.54 ±0.19d 1.37 0.21c 2.01 ± 0.33
IgM (normal 0.4-1.6) 1.23 ± 0.20 0.87 ± 0.18 0.42 ± 0.18a 0.44 ± o.O9b 0.92 ± 0.12
ap<0.O1, bp<O.Ol, cP<0.02, dp<0.05 (compared with presentation values). nd, not done.
had staging laparotomy between 1974 and 1983, none of
whom had had prophylactic penicillin and only six
preoperative pneumococcal vaccine, only two severe infec-
tions were seen in the absence of persistent or recurrent
Hodgkin's disease. One patient (6 months following 'mantle'
radiotherapy) developed fulminating meningococcal sep-
ticaemia and died; the other (6 years following 'mantle'
radiotherapy) was successfully treated for pneumococcal
meningitis.
The only patient to have had a recurrence of Hodgkin's
disease after the 10 year assessment did show deteriorating
cellular immune responses, presumably as a non-specific
marker of disease recurrence.
Many of the immunological tests employed in the study
are relatively outdated and it is possible that newer techni-
ques may give more meaningful results in terms of both
immune function and clinical correlation; however, our
overall impression after 10 years of study of basic
immunological tests is that follow-up assessments have little
relevance to the clinical situation unless the abnormalities are
severe.
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